Return to homepagePandemic Pact

Adaptive Platform Trials: Expanding impact

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA481171

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2026
    2030

  • Known Financial Commitments (USD)

    $1,993,858.92

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia

  • Lead Research Institution

    Monash University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

I am an intensive care physician who leads clinical trials. I have world leading expertise in a new type of trial design, termed an adaptive platform trial, that generates reliable evidence to guide care faster and at lower cost than previous methods.less thanbrgreater thanless thanbrgreater thanI will generate new knowledge by leadership of REMAP-CAP, a trial that has generated evidence about best treatment for patients with severe COVID-19 infection and apply adaptive platform trial methods to other disease areas.